An Analysis of the Role of Macrophages in Cancer Treatment

Cancer is like a mob city within the body. Cells decide to ignore any laws and regulations that are there and refuse to die when they should. This anarchy can lead to the formation of tumours, which can invade nearby tissues and potentially spread to distant parts of the body, a process known as metastasis (Cancer Research UK, 2018).

Brief Overview of Cancer and the Immune System 

The immune system is the body’s security force, always on the lookout for perpetrators, and consists of various cells and organs, including white blood cells, the spleen, and the lymph nodes, all working together to keep the body safe. It has two main branches: the innate immune system and the adaptive immune system. Think of the innate immune system as the first responders - they react fairly quickly to any signs of trouble but aren’t very specific. They include cells like macrophages that mitigate anything suspicious.

The adaptive immune system, however, is more like a specialised task force. It takes a bit longer to respond but is highly specific. This system includes T-cells and B-cells which take note of past invaders and can attack quickly if they show up again.

Due to cancer’s advanced nature, it can disguise itself, send out signals to suppress the immune response, or create a hostile environment that makes it difficult for immune cells to function. This is why cancer can sometimes grow unchecked despite the immune systems best efforts (National Cancer Institute, 2021). 

Scientists have recently developed treatments that help the immune system recognise and attack cancer cells more effectively. Known as immunotherapy, this approach includes strategies like checkpoint inhibitors, which release brakes on immune cells, and CAR-T cell therapy, where a patients T-cells are modified tobetter target cancer (Cancer Research Institute, 2019).

Macrophages in the Tumour Microenvironment (TME)

A microenvironment is a complex ecosystem composed of cancer cells, immune cells, blood vessels, extracellular matrix, and various signaling molecules (Toledo et al., 2024).

Among the immune cells in the TME, macrophages can be pivotal. These cells, known as tumour-associated macrophages (TAMs) can be a double-edged sword- they can either support the body’s defence against cancer or, more often, be coopted by the tumour to aid in its growth and spread. (Toledo et al., 2024)

Types of Macrophages

Macrophages originate from monocytes, a type of white blood cell and can be found in almost every tissue of the body. Once they are identified they can be differentiated into two different categories: M1 and M2 macrophages:

M1 Macrophages: M1 macrophages are the immune system’s frontline soldiers, always ready for battle. They're activated by signals from pathogens or inflammatory cytokines, and they excel at attacking and destroying invaders. They produce high levels of pro-inflammatory cytokines, reactive oxygen species (ROS), and nitric oxide (NO), which help to kill pathogens and cancer cells (Kenhub, n.d.). If there’s a “good cop, bad cop” situation M1 macrophages would be the bad cops. They can often times be quite aggressive and lead to inflammation around the area.

M2 Macrophages: In contrast, M2 macrophages are the “good cops” who focus on healing and repair. These cells are activated by ant-inflammatory cytokines and are involved in tissue repair, wound healing, and maintaining homeostasis. They produce anti-inflammatory cytokines, growth factors, and enzymes to help rebuild damaged tissues and suppress inflammation. (Kenhub, n.d.) Unfortunately, they can also be co-opted by tumours to support cancer growth and metastasis. (Biology LibreTexts, 2018)

Mechanisms of Macrophage Action in Cancer

Phagocytosis and Antigen Presentation: Phagocytosis is the process by which macrophages engulf and digest cancer cells. Once a macrophage has devoured a cancer cell, it breaks it down into smaller pieces called antigens. These antigens are then presented on the macrophage surface to alert other immune cells, particularly T-cells, to the presence of cancer. This process is crucial for initiating a targeted immune response against the tumour. (Li et al., 2023)

Secretion of Cytokines and Growth Factors: Macrophages are also prolific producers of cytokines and growth factors which are the messenger pigeons of the immune system. These molecules can either promote or inhibit inflammation, depending on the context. In the TME, macrophages often secrete cytokines that suppress the immune response, creating a more comfortable environment for the tumour. However, they can also produce factors that stimulate the immune system to attack cancer cells.

Interaction with Other Immune Cells: With their frequent interactions with other cells, macrophages are the immune system's social butterflies. They set up a comprehensive immune response by  being in constant communication with natural killer (NK) cells, B-cells, and T-cells. For instance, by presenting antigens and secreting cytokines that improve T cell activity, macrophages can activate T-cells. They also contribute to a stronger and quicker tumour response by attracting additional immune cells to the tumour location.

Therapeutic Strategies Targeting Macrophages in the Tumour Microenvironment

Reprogramming TAMs: Converting M2 to M1 Phenotype: A promising approach to the treatment is to reprogram the pro-tumour M2 phenotype to the anti-tumour M1 phenotype. As stated earlier, M1 macrophages are the immune system’s warriors, producing inflammatory cytokines and attacking cancer cells. Researchers are developing drugs and molecules to induce this switch, enhancing the body’s natural anti-tumour response. (Toledo et al.,2024b)

Depletion of TAMs: Using Drugs to Reduce Macrophage Numbers: Another strategy is simply reducing the number of TAMs in the TME. This can be achieved using drugs that specifically target and deplete macrophages. By reducing the number of TAMs, the tumour loses some of its support system, making it more vulnerable to other treatments (Sadhukhan and Seiwert, 2023).

Blocking Recruitment: Inhibiting Signals that Attract Macrophages to Tumours: Tumours often send distress signals that attract macrophages to their location; therefore, blocking these signals would jam their communication lines. By inhibiting the recruitment of macrophages to the tumour site, researchers aim to prevent the build-up of TAMs and disrupt the tumour’s ability to manipulate the immune system.

Enhancing Phagocytosis: Boosting Macrophage's Ability to Engulf Cancer Cells: Phagocytosis is the process by which macrophages engulf and digest cancer cells, much like a Pac-Man gobbling up dots. Enhancing this ability can make macrophages more effective at clearing cancer cells from the body. Researchers are exploring various ways to boost phagocytosis, including the use of antibodies and other molecules that can enhance the macrophages’  appetite for cancer cells.

Nanotechnology and Macrophages in the Tumour Microenvironment

By using nanoparticles, researchers can deliver drugs directly to tumour associated macrophages (TAMs), enhancing their ability to fight cancer. Nanoparticles are tiny, engineered particles that can be loaded with therapeutic agents and designed to target specific cells. Imagine them as microscopic delivery drones, programmed to seek out and infiltrate the TME. These nanoparticles can be engineered to carry drugs that either reprogram TAMs from a pro-tumour (M2) to an anti-tumour (M1) phenotype or deplete them all together. (Hu et al., 2019). Nanoparticles can be coated with ligands that specifically bind to receptors on TAMs, ensuring that the drugs are delivered precisely where they are needed, and this minimises side effects and maximises therapeutic impact.

Nanotechnology offers many advantages in targeting macrophages:

1. Precision Targeting: It’s like having a GPS-guided missile that only hits the bad guys. Nanoparticles can be designed to specifically target TAMs, reducing off target effects and enhancing the efficacy of the treatment. (Ummarino et al.,2020)

2. Controlled Release: Nanoparticles can be engineered to release their payload in a controlled manner, ensuring a sustained therepeutic effect.

3. Enhanced Penetration: Due to their small size, nanoparticles can penetrate deep into the tumour tissue, reaching areas that might be inaccessible to conventional drugs. (Ding et al., 2022)  

4. Multifunctionality: Nanoparticles can be designed to carry multiple drugs or therapeutic agents, allowing for combination therapies that can simultaneously target different aspects of the tumour and its microenvironment. (Ummarino et al., 2020b)

Conclusion

Macrophages in the TME are versatile and influential players in cancer progression. They can either support or hinder tumour growth, depending on their polarisation and the signals they receive from the TME. Therapeutic strategies targeting TAMs include reprogramming them from a pro-tumour to an anti-tumour phenotype, depleting their numbers, blocking their recruitment, and enhancing their phagocytic abilities. However, the heterogeneity of TAMs and the complexity of the TME present significant challenges, and potential side effects and resistance mechanisms must be carefully considered.

Reference list

Cancer Research UK. (2017). Body systems and cancer. [online] Available at: https://www.cancerresearchuk.org/about-cancer/what-is-cancer/body-systems-and-cancer/the-immune-system-andcancer. [Accessed 5 Sep. 2024].

Ding, X., Sun, X., Cai, H., Wu, L., Liu, Y., Zhao, Y., Zhou, D., Yu, G. and Zhou, X. (2022). Engineering Macrophages via Nanotechnology and Genetic Manipulation for Cancer Therapy. Frontiers in Oncology, 11. doi:https://doi.org/10.3389/fonc.2021.786913.

Google.com. (2024). Redirect Notice. [online] Available at: https://www.google.com/url?sa=i&url=https%3A%2F%2Fshop-us.kurzgesagt.org%2Fproducts%2Fimmune-infographicposter&psig=AOvVaw2WNMWFXlS45kFB78781FWp&ust=1725614579722000&source=images&cd=vfe&opi=89978449&ved77O9q4gDFQAAAAAdAAAAABAR [Accessed 5 Sep. 2024].

Hu, G., Guo, M., Xu, J., Wu, F., Fan, J., Huang, Q., Yang, G., Lv, Z., Wang, X. and Jin, Y. (2019). Nanoparticles Targeting Macrophages as Potential Clinical Therapeutic Agents Against Cancer and Inflammation. Frontiers in Immunology, 10. doi:https://doi.org/10.3389/fimmu.2019.01998.

Kenhub. (n.d.). Macrophages. [online] Available at: https://www.kenhub.com/en/library/anatomy/macrophages.

Li, M., Yang, Y., Xiong, L., Jiang, P., Wang, J. and Li, C. (2023). Metabolism, metabolites, and macrophages in cancer. Journal of Hematology & Oncology, 16(1). doi:https://doi.org/10.1186/s13045-023-01478-6.

National Cancer Institute (2021). What Is Cancer? [online] National Cancer Institute. Available at: https://www.cancer.gov/about-cancer/understanding/what-is-cancer.

Sadhukhan, P. and Seiwert, T.Y. (2023). The role of macrophages in the tumor microenvironment and tumor metabolism. Seminars in Immunopathology. doi:https://doi.org/10.1007/s00281-023-00988-2.

Staff, C. (2019). How does the immune system work? [online] Cancer Research Institute. Available at: https://www.cancerresearch.org/blog/april-2019/how-does-the-immune-system-work-cancer. [Accessed 5 Sep. 2024].

Toledo, B., Linrui Zhu Chen, María Paniagua-Sancho, Juan Antonio Marchal, Macarena Perán and Giovannetti, E. (2024a). Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy. Journal of Hematology & Oncology, 17(1). doi:https://doi.org/10.1186/s13045-024-01559-0.

Ummarino, A., Gambaro, F.M., Kon, E. and Torres Andón, F. (2020b). Therapeutic Manipulation of Macrophages Using Nanotechnological Approaches for the Treatment of Osteoarthritis. Nanomaterials, 10(8), p.1562. doi:https://doi.org/10.3390/nano10081562.